Latest Financial Results News

PT ANTAM TBK sustained strong operational performance in Q1 2026 with robust gold and nickel sales amid favourable market trends, while pushing forward strategic mineral downstreaming projects including Indonesia's integrated battery ecosystem.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.

Tinybeans Group has reported its inaugural EBITDA-positive quarter with US$8K profit, driven by strong subscription growth, e-commerce expansion, and operational efficiencies following the Qeepsake acquisition.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Rakon Limited has swung back to profit in FY26, reporting a 24% revenue lift and doubling EBITDA, while Bourns' takeover offer edges closer to completion with 85% shareholder acceptance and pending French regulatory approval.

Xamble Group stabilised revenue at A$1.64 million in Q1 2026 while narrowing its group EBITDA loss slightly despite ramped-up technology spending. The company completed its acquisition of YouthsToday, tripling its influencer base and locking in three commercial contracts worth A$1.17 million.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

INOVIQ Limited is on track to complete its EXO-OC™ ovarian cancer screening study by mid-2026 and is accelerating its CAR-exosome therapy program, supported by a strong cash position of A$11.9 million.

Whitehaven Coal’s March quarter production fell 14% due to seasonal wet weather in Queensland, but coal prices rose sharply and refinancing cut interest costs by up to A$55 million annually.

Vitrafy Life Sciences completed Phase II of its U.S. Military platelet cryopreservation study with strong results for a simplified no-wash process, accelerating commercial interest and progressing FDA device registration despite manufacturing delays.

Barramundi Limited’s portfolio took a heavy hit in Q1 2026, with a 15.4% adjusted NAV decline amid AI disruption anxieties and geopolitical tensions. The fund responded by trimming tech holdings and adding miners BHP and Rio Tinto, betting on copper demand and scale advantages.

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.